Group 1: Financial Performance and Product Sales - In 2025, the sales revenue of DK185 corneal reshaping lenses accounted for 5.71% of hard lens sales, while scleral lenses accounted for 1.23% [3] - The average price of existing corneal reshaping lenses decreased in 2025, but the overall profit margin for hard lens business declined due to increased sales and management expenses [6] - The revenue from frame glasses and other optical products grew by 19.49%, reflecting the implementation of a comprehensive optical service strategy [8] Group 2: Product Development and Market Strategy - The company is focusing on promoting ultra-high oxygen permeability corneal reshaping lenses and scleral lenses in 2026, with plans to expand the user base by introducing adult corneal reshaping lenses [3] - The company has several products in clinical trials, including the OVCTEK 210FX corneal reshaping lens and a hydrogen peroxide care solution [4] - The company is cautious about expanding optical terminals, prioritizing feasibility assessments and quality [5] Group 3: Investor Relations and Market Outlook - The online meeting on March 30, 2026, included 58 participants from various securities firms and investment institutions [2] - The company is exploring overseas sales through both offline and cross-border e-commerce, with ongoing registration for medical devices in Southeast Asia [9] - The company plans to enhance its product offerings in the eye health sector, including functional soft lenses and high-end soft lens materials [4][7]

Group 1: Industry Overview - The medical device market in China is experiencing rapid growth, with the market size projected to increase from 440.3 billion yuan in 2017 to 1,154.4 billion yuan by 2024, representing a compound annual growth rate (CAGR) of 14.76%, significantly higher than the global CAGR of 4.82% during the same period [2] - By 2025, the market size is expected to reach 1.24 trillion yuan, and by 2030, it is anticipated to exceed 1.66 trillion yuan, driven by government support and increasing per capita medical spending [2] - The establishment of the Anhui Medical Device Innovation Alliance aims to enhance collaboration within the industry and promote the development of high-end medical imaging equipment [2] Group 2: Company Developments - Companies in the medical device sector are focusing on high-end product development, with significant investments in research and development [4] - Opcon Vision has successfully developed a high-permeability oxygen material, DK185, which exceeds industry standards, leading to the launch of new products such as corneal reshaping lenses [4] - Anhui Zhongke Ion Medical Technology Equipment Co., Ltd. has created China's first and the world's most compact superconducting proton therapy system, with a domestic production rate of over 95%, currently in clinical trial [4] - Anhui Tongling Bionic Technology Co., Ltd. has completed clinical trial enrollment for its "interventional ventricular assist system," which has been approved for expedited review by the National Medical Products Administration [5]